Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Regen BioPharma (RGBP) over the last 11 years, with Q2 2025 value amounting to $17733.0.

  • Regen BioPharma's Non-Current Assets changed 0.0% to $17733.0 in Q2 2025 from the same period last year, while for Dec 2025 it was $35466.0, marking a year-over-year decrease of 5000.0%. This contributed to the annual value of $17733.0 for FY2024, which is 9203.3% down from last year.
  • Regen BioPharma's Non-Current Assets amounted to $17733.0 in Q2 2025, which was down 0.0% from $17733.0 recorded in Q1 2025.
  • Regen BioPharma's Non-Current Assets' 5-year high stood at $1.1 million during Q2 2021, with a 5-year trough of $17733.0 in Q4 2023.
  • Moreover, its 5-year median value for Non-Current Assets was $90881.5 (2021), whereas its average is $164481.3.
  • In the last 5 years, Regen BioPharma's Non-Current Assets surged by 518078.02% in 2021 and then plummeted by 9203.3% in 2023.
  • Regen BioPharma's Non-Current Assets (Quarter) stood at $94084.0 in 2021, then surged by 136.58% to $222580.0 in 2022, then plummeted by 92.03% to $17733.0 in 2023, then changed by 0.0% to $17733.0 in 2024, then changed by 0.0% to $17733.0 in 2025.
  • Its Non-Current Assets stands at $17733.0 for Q2 2025, versus $17733.0 for Q1 2025 and $17733.0 for Q4 2024.